NEW YORK, March 26, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Newmont Corporation (NYSE: NEM) between February 22, 2024 and October 23, 2024, inclusive (the "Class Period"), of the important April 1, 2025 lead plaintiff deadline.So what: If you purchased Newmont securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to do next: To ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Monolithic Power Systems, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Monolithic Power Systems common stock between February 8, 2024, and November 8, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 7, 2025, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Monolithic Power Systems made materially false and misleading statements regarding its voltage regulator modules and power management integrated circuits, which suffered from performance and air quality issues [5]. - It is claimed that these defects negatively impacted Nvidia's products that utilized Monolithic Power Systems' components, leading to significant business, financial, and reputational risks for the company [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased AppLovin Corporation securities between May 10, 2023, and February 25, 2025, of the May 5, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by May 5, 2025, to serve as lead plaintiff [2] - Investors can join the class action by visiting the provided link or contacting the law firm directly [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that defendants provided misleading information regarding AppLovin's financial growth and stability, including confidence in its AXON 2.0 digital ad platform [4] - Defendants reportedly disseminated materially false statements while concealing adverse facts, such as the use of a "backdoor installation scheme" that inflated installation numbers and profitability [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased enCore Energy Corp. securities between March 28, 2024, and March 2, 2025, about the May 13, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought enCore securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is May 13, 2025, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3]. - The firm’s founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, showcasing the firm's reputation and expertise [3]. Group 3: Case Allegations - The lawsuit alleges that enCore made false and misleading statements and failed to disclose critical information regarding its internal controls and financial reporting [4]. - Specific claims include enCore's inability to capitalize certain exploratory and development costs under GAAP, leading to increased net losses [4]. - The misleading statements about enCore's business operations and prospects resulted in investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased TransMedics Group, Inc. securities between February 28, 2023, and January 10, 2025, of the April 15, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased TransMedics securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lead plaintiff must file a motion with the Court by April 15, 2025, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that TransMedics made materially false and misleading statements, including the use of kickbacks and fraudulent practices to generate revenue [5] - It is claimed that TransMedics engaged in unsafe practices and lacked proper safety oversight, which increased regulatory scrutiny [5] - The misleading statements about the company's business and operations led to investor damages when the true information became public [5]

Core Viewpoint - A class action lawsuit has been filed against The Bancorp, Inc. for alleged misleading statements and failures to disclose significant risks related to its loan portfolio and financial reporting during the Class Period from January 25, 2024, to March 4, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that The Bancorp underrepresented the risk of default on its REBL loan portfolio and that its credit loss methodology was inadequate [5]. - It is alleged that there were material weaknesses in the company's internal controls over financial reporting and that its financial statements lacked independent auditor approval [5]. - The lawsuit asserts that these issues led to misleading positive statements about the company's business and operations [5]. Group 2: Participation Information - Investors who purchased The Bancorp securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the court by May 16, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Grocery Outlet Holding Corp. securities between November 7, 2023, and May 7, 2024, of the March 31, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Grocery Outlet securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 31, 2025 [3]. - The lawsuit alleges that during the Class Period, Grocery Outlet made misleading statements about its transition to new systems, which concealed potential setbacks affecting profitability [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Lab USA, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on April 28, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased Rocket Lab securities between November 12, 2024, and February 25, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - The lawsuit claims that Rocket Lab made false or misleading statements regarding delays in their operations and the reliability of their contracts, which led to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Geron Corporation securities between June 7, 2024, and February 25, 2025, alleging misleading statements regarding the company's revenue outlook and growth potential [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Geron Corporation made false and misleading statements about its projected revenue and growth, downplaying risks associated with seasonality and macroeconomic factors [5]. - It is alleged that Geron's reports on the launch success of Rytelo, a telomerase inhibitor, did not accurately reflect the challenges faced in the market, including competition and the need for ongoing monitoring [5]. - The lawsuit indicates that when the true situation became known, investors suffered damages due to the misleading information provided by Geron [5]. Group 2: Class Action Participation - Investors who purchased Geron securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must file their motion by May 12, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of ESSA Pharma Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 25, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The lead plaintiff must file a motion with the Court by March 25, 2025, to represent other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that ESSA Pharma Inc. failed to disclose critical information regarding the efficacy of masofaniten in combination with enzalutamide, misleading investors about its effectiveness in treating prostate cancer [4]. - It is claimed that the M-E Combination Study was unlikely to meet its primary endpoint, leading to overstated clinical and commercial prospects for masofaniten [4]. - The public statements made by the defendants were deemed materially false and misleading, resulting in investor damages when the true information became public [4].